News

Technology News

Plexcera Receives Exclusive Development License

Monday, September 16, 2013 5:16:00 AM PDT | VentureDeal
   Vero Beach, Florida  --  Plexcera Therapeutics has been granted an exclusive therapeutic development license from the Mount Sinai Innovation Partners, part of the Icahn School of Medicine at Mount Sinai.

Plexcera will be able to commercially develop recombinant human acid ceramidase (rhAC) to potentially treat diseases such as Farber Disease and Cystic Fibrosis.

These two childhood diseases are caused by recessive inherited mutations in the gene encoding rhAC, and there is currently no therapy for either condition.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1